Effects of GRA in Patients With Type 1

Inclusion Criteria: 1. Men and women between the ages of 18 and 65 years old, inclusive, at the time of screening; 2. Females of non-child bearing potential must be ≥ 1 year post-menopausal or documented as being surgically sterile. Females of child bearing potential must agree to use two methods of contraception during the entire study and for an additional 3 months after the end of dosing with the investigational product; 3. Male subjects must be willing to use clinically acceptable method of contraception during the entire study and for an additional 6 months after the end of the treatment period; 4. Diagnosed with Type 1 diabetes based on clinical history or as defined by the current American Diabetes Association (ADA) criteria for \> 5 years; 5. Treatment with a stable insulin regimen for at least 8 weeks before screening with continuous subcutaneous insulin infusion (CSII) via an insulin pump; 6. Currently using a Continuous Glucose Monitoring (CGM) system; 7. HbA1c ≤ 8.5 % at screening; 8. A minimum weight of 50kg; 9. eGFR ≥ 60 mL/min/1.73m² 10. Able to provide written informed consent approved by an Institutional Review Board (IRB). Exclusion Criteria: 1. History or evidence of clinically-significant disorder or condition that, in the opinion of the Investigator, would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion; 2. History of pancreatitis, medullary thyroid carcinoma and/or liver disease; 3. Clinically significant diagnosis of anemia; 4. Body Mass Index (BMI) \< 18.5 kg/m2 and/or weight less than 50kg; 5. Whole blood donation of 1 pint (500 mL) within 8 weeks prior to Screening. Donations of plasma, packed RBCs, platelets or quantities less than 500 mL are allowed at investigator discretion; 6. Current or recent (within 1 month of screening) use of diabetes medications other than insulin; 7. Women who are pregnant or lactating/breastfeeding; 8. Unable or unwilling to follow the study protocol or who are non-compliant with screening appointments or study visits; 9. Any other condition(s) that might reduce the chance of obtaining study data, or that might cause safety concerns, or that might compromise the ability to give truly informed consent.